Changes in inflammatory mediators in experimental periodontitis in the rhesus monkey. by Smith, M.A. et al.
Vol. 61, No. 4INFECTION AND IMMUNITY, Apr. 1993, p. 1453-1459
0019-9567/93/041453-07$02.00/0
Copyright X 1993, American Society for Microbiology
Changes in Inflammatory Mediators in Experimental
Periodontitis in the Rhesus Monkey
M. A. SMITH,' L. D. BRASWELL,' J. G. COLLINS,2 D. L. BOYD,2 M. K. JEFFCOAT,3 M. REDDY,3
K. L. LI,4 S. WILENSKY,4 R. VOGEL,4 M. ALFANO,4 AND S. OFFENBACHERl 2*
University ofNorth Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-74552; Yerkes Regional
Primate Research Center, Atlanta, Georgia 303221; University ofAlabama at Birmingham,
Birmingham, Alabama 352943; and Block Drug Company, Inc., Jersey City, New Jersey4
Received 29 July 1992/Accepted 21 January 1993
Ligature-induced periodontitis was monitored for 6 months in eight Macaca mulatta monkeys to examine
clinical status, radiographic bone level, and crevicular fluid (CF) levels of prostaglandin E2 (PGE2),
thromboxane B2 (TxB2), interleukin-lf (IL-1*), tumor necrosis factor alpha, and leukotriene B4 (LTB4). A
split-mouth design was used, with eight ligated teeth and eight contralateral nonligated teeth which develop
soft-chow-promoted (spontaneous) disease. Ligated sites experienced an average attachment loss of 0.94 mm
per site and linear bone loss of 0.88 mm per site, with spontaneous-periodontitis sites experiencing
approximately half the loss of ligated sites. The CF mediator levels showed increased levels of PGE2 and TxB2
at the ligated sites, as compared with the spontaneous sites, with no significant contralateral differences in the
IL-11 or LTB4 responses. The concentrations of LTB4 in CF reached an early threefold peak over the baseline
level at 1 month. By 2 months there was a statistically significant threefold elevation in CF-PGE2 in the ligated
sites and a twofold elevation in the spontaneous sites as compared to the baseline level (P = 0.041 and 0.008,
respectively). The monocyte product IL-11 increased sharply at 2 months and returned to the baseline level by
6 months at both ligated and nonligated sites. Tumor necrosis factor alpha in CF was below the limit of
detection at all sites throughout the experiment (i.e., <2 ng/ml). The selective elevation of both PGE2 and TxB2
in ligated sites, compared with levels in spontaneous sites, in the presence of similar levels of LTB4 and IL-1,8
provides further evidence that these molecules regulate the magnitude of the tissue-destructive response in
progressive periodontitis.
Experimental periodontitis in the nonhuman primate has
proven to be a useful model for understanding the molecular
basis of the inflammatory lesion (14, 15), the virulence
properties of putative periodontal pathogens (7), and the
potential efficacy of pharmacological agents (13, 14, 27) in
human periodontal disease. The rhesus monkey develops
periodontitis spontaneously in captivity with certain charac-
teristics that are similar to the disease in humans in that it
appears to be relatively slow in progressing and demon-
strates increased severity with age (1, 3, 4, 11, 12, 20, 21).
Experimental models which employ ligatures and/or soft
chow to promote plaque retention accelerate disease pro-
gression. Ligature placement results in a rapid loss of about
1 mm of probing attachment per site in about 1 to 2 months
which is followed by a parallel loss of bone by 3 to 6 months
(14, 15). In these animals, disease progression occurs at
nonligated sites but results in a slower attachment and bone
loss pattern which requires about 1 year to reach 1 mm per
site (14). It is not entirely clear exactly how these two
disease models relate to human disease states. Longitudinal
data on the natural progression of periodontitis in humans
suggest that disease progression can occur either rapidly in
episodes or more slowly in a chronic, almost linearly pro-
gressive manner (for a review, see reference 6). It seems
reasonable to suggest that the differences in clinical presen-
tation when these two types of progression are compared
may be due to either a simple difference in chronological
development or different mechanisms or sequences of cellu-
lar recruitment and activation. Clinically, the ligature model
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in the rhesus monkey mimics the more acute episodic loss
that can occur in humans, and the soft-chow, or "spontane-
ous periodontitis, model relates to the more chronic pro-
gressive lesion in humans. Therefore, the intent of this
report is to provide data describing the chronological devel-
opment of these two types of lesions and to contrast some of
the underlying molecular inflammatory events which occur
in these two forms of periodontal disease. We have focused
our studies on relating the changes in clinical disease expres-
sion to the changes in the crevicular fluid (CF) levels of
prostaglandin E2 (PGE2), thromboxane B2 (TxB2), leuko-
triene B4 (LTB4), interleukin-13 (IL-10), and tumor necrosis
factor alpha (TNF-ot). Our previous studies have demon-
strated CF increases in both PGE2 and TxB2 in both forms of
this disease model (15-18). Our intent is to confirm these
findings and to relate these changes temporally to these other
important inflammatory mediators. LTB4 is a neutrophil
product that is vasoactive and plays a significant role in
neutrophil and monocyte recruitment and activation (for a
review, see reference 2). We have previously described
elevated LTB4 levels in adult and juvenile periodontitis (17)
as well as in gingivitis (6). In this report we establish the
relationship between LTB4 elevation and longitudinal dis-
ease progression. IL-lp and TNF-a are principally products
of activated monocytes which are critical for lymphocytic
clonal expansion and inflammatory cell activation, and both
are potent stimulators of osteoclastic bone resorption (for a
review, see reference 8). Data presented reveal insight into
the sequence of cellular activation events which occur in the
rhesus monkey and suggest underlying mechanisms of
pathogenesis for progressing lesions. We provide data in
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support of an orchestrated, sequential model for cytokine-
and lipid mediator-directed periodontal destruction.
MATERIALS AND METHODS
Experimental animals. Eight rhesus monkeys (Macaca
mulatta) with clinical signs of periodontitis but showing no
systemic illness were selected for this study. Animals were
housed at Yerkes Regional Primate Research Center as
described previously (1). In addition to their use in the
present study, this group of animals served as a control
group for a study of a topical intraoral gel formulation. The
placebo gel did not apparently affect plaque accumulation or
the rate of disease progression, as compared with results of
our previous studies (14, 18). Prior to the study there was a
2-week chair-training period for the monkeys. Each day the
animals were removed from their cages with a rigid collar
with an interlocking pole (Primate Products). The animals
were guided into a passive restraining chair with an inter-
locking neck plate (Primate Products) that isolated and
restrained the monkey's head. Any monkey who resisted
daily handling or who failed to learn the chairing routine with
a minimum of apparent stress was excluded.
Disease model. The disease model employed a split-mouth
design. A Cavitron prophylaxis was completed on the left
side of the mouth 2 weeks before the study began. At the
beginning of the study, the animals were placed on a diet of
water-softened Purina monkey chow supplemented with soft
fruit. On the left side of the mouth, teeth 9, 12, 13, 14, 19, 20,
21, and 24 were monitored for the development of soft-chow-
promoted periodontal disease. These teeth were not ligated
and are designated spontaneous sites in this report. Ligature-
induced periodontitis was started on the right side of the
mouth by ligating eight test teeth (teeth 3, 4, 5, 8, 25, 28, 29,
and 30) at the cementoenamel junction with 3-0 silk. Daily
log sheets were used to record any lost ligatures, which were
replaced at 2-week intervals.
Clinical examinations. On examination days, five separate
stations were set up and the monkeys were rotated through
each station to minimize the amount of time that each
monkey was sedated. At the first station, animals were
anesthetized with 4 to 5 mg of Telezol (Aveco Company,
Inc., Fort Dodge, Iowa) per kg, administered intramuscu-
larly, which we found to be superior to ketamine since it
reduced salivation and minimized seizures. A veterinarian or
veterinarian's assistant anesthetized, weighed, and collected
a blood sample from each animal and subsequently followed
that animal through all stations to monitor anesthesia and
provide supplement, if needed. Each station had one oper-
ator who collected all samples, clinical indices, or X-rays for
all animals to eliminate intraoperator variability in data
collection and clinical assessments. This same operator was
present at all examination visits. The animals were moved
sequentially through the stations-anesthesia, radiographs,
CF sampling, clinical indices, and ligature placement-prior
to returning to the recovery area. Thus, each animal was
anesthetized for a total of about 1 h for each exam. For each
clinical index three sites, the mesiobuccal, buccal, and
distobuccal, were checked on each tooth by evaluation
criteria previously described (14, 15). Briefly, gingival ery-
thema was evaluated with an index of 0 to 4, with 0 to 3
indicating none, mild, moderate, and severe, respectively; a
score of 4 was given if frank ulceration or necrosis was
present. Bleeding on probing (using a controlled-force Flor-
ida probe [25 g]) was recorded as either present or absent at
each site. Pocket depths and cementoenamel junction levels
were recorded to the nearest 0.1 mm with the Florida probe,
using the pocket measuring handpiece to enable Ramfjord
attachment level calculations. Two weeks before the study
began, all clinical measurements for all animals were col-
lected. At the start of the study, these parameters were
measured again. This enabled the comparison of all clinical
measurements obtained on the right side of the mouth, which
did not have a prophylaxis, at two time points to provide
estimates of the variability of repeated measures.
Radiographic analyses. Standardized radiographs were
taken as described previously, with a constant focal distance
of 60 in. (ca. 152 cm) from the film (9). The X-ray unit was a
Tokya Emix Corporation Model D, TR-20. Customized Rinn
bite blocks and high-speed Type E Kodak film were used.
The monkey's head was held by a head restraint to prevent
any movement of the head and to standardize the geometry
and the distance between the X-ray unit and the teeth.
Mandibular molar and premolar X-rays were taken on the
right and left sides for each monkey at day zero, 3 months,
and 6 months.
Radiographs were digitized as previously described (9)
with a video camera coupled to an analog-to-digital con-
verter capable of storing an entire video frame in solid-state
memory in one frame time (0.05 s). The frame grabber
(PCVISION PLUS; Imaging Technologies, Woburn, Mass.)
is capable of storing two image frames, with a spatial
resolution of 512 by 512 pixels and a 256-level gray scale, by
using a microcomputer (Compaq 386/20) as the central
processing unit. Since slight variations in film processing or
voltage to the X-ray tube may result in differences in
contrast in the resultant films, the nonparametric gamma
correction algorithm of Ruttimann (22) was used to correct
for differences in contrast between the pretreatment and
posttreatment radiographs. If necessary, planar geometric
discrepancies were corrected by applying an aphine warp
algorithm previously described (26). The distance between
the cementoenamel junction and the crest of the alveolar
bone was determined for mesial and distal root surfaces
according to the method described by Jeffcoat et al. (27). The
measurement was corrected for the magnification of the
radiograph in the image processing system. Millimeters of
bone loss at each site was determined for both ligated and
spontaneous sites at day zero, 3 months, and 6 months. The
millimeters of loss was subtracted from the loss at day zero
to determine the amount of bone lost during the study.
Previous studies have shown the error of this method in
estimating bone loss to be less than 0.08 mm on the original
radiograph (27). All radiographs were digitized and analyzed
blindly. Each radiograph for digitized analysis was identified
by number only; thus each bone height determination was
made totally independently with no before-versus-after bias.
Biochemical analyses. CF samples were used for the deter-
mination of PGE2, TxB2, LTB4, and IL-1p. The collection,
storage, and analyses of these samples have been described
previously (6, 15). Briefly, CF samples were collected and
the volume was measured with a Model 6000 Periotron
(Harco Electronics Ltd., Canada). Three CF samples were
taken from each side of the mouth for each mediator. Site
pairing was maintained for each mediator at all time points.
The PGE2 and TxB2 were assayed by radioimmunoassay
(RIA) as previously described (15). Standard curves and
internal control samples from two sets of samples indicated
technical RIA problems. These two datum points (PGE2 at 1
month and TxB2 at 2 months) were omitted from the data
analysis and the figures. LTB4 was assayed by a slight
modification of the same RIA with immunoreagents supplied
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by Advanced Magnetics. IL-13 and TNF-a levels were
quantitated by using the Cistron enzyme-linked immunosor-
bent assay (ELISA) kits, graciously provided by Cistron.
The IL-10 assay uses human IL-1B as a standard, a plate-
bound, mouse anti-human IL-1lB monoclonal antibody, and
an antihuman IL-lp rabbit polyclonal antiserum. We had
previously found these human IL-1B and TNF-ot Cistron
reagents to cross-react with rhesus IL-lp and TNF-a suffi-
ciently to theoretically permit detection in rhesus CF. These
experiments were performed on rhesus tissue samples (data
not shown). However, since TNF-a could not be detected
within the CF by using Cistron reagents, we also tested
Medgenix TNF-a reagents with similar results, thereby
confirming that the levels of TNF-ot were below our detec-
tion level of 2 ng/ml.
Computations and statistics. After the biochemical analy-
ses were completed, an interactive computerized data link
system for fitting standard curves and for computation of
unknowns was used. All clinical data were stored, sorted,
and collated in spreadsheet files.
Data from multiple sites within each monkey were pooled
to provide single-animal means ± standard error, with the
monkey as the unit of observation. These values were then
pooled to obtain group estimates. This approach was used
for all clinical and biochemical data. By using a repeated-
measures analysis of variance (ANOVA), comparisons were
made for both disease model (ligated versus spontaneous)
and time. When significant effects were found by repeated-
measures ANOVA, pairwise comparisons were made by
paired or nonpaired t tests. An alpha level of less than 0.05
was considered statistically significant.
RESULTS
General comments. During the first 3 months of the study
most monkeys showed a weight loss of approximately 5% of
their baseline body weight. This may have been due to the
daily routine of chairing or to a flulike viral infection that
spread throughout the primate colony, including our study
animals. By the 3-month clinical evaluation, most of the
weights had stabilized and remained stable for the remainder
of the study. Periodontal disease progression in this model
and changes in CF-PGE2 were found to be essentially
identical to those in our previous experiments which did not
use either a placebo gel or chairing technique (14, 15).
Changes in clinical status. As expected, both the ligated
and nonligated sites showed a significant time-dependent
increase in redness and bleeding on probing. Figure 1 shows
the average percentage of sites which demonstrated an
increase in redness scores. This shows that ligated teeth had
an average of 28.6% sites that showed an increase in redness
score (of 1 or more units) at 1 month, as compared with the
baseline level. By 2 months, 46.7% of the sites on ligated
teeth showed an increase in redness score of 1 unit or more.
The redness scores for both the ligated and spontaneous
groups increased with time over the baseline levels at P =
0.003 and P = 0.0016, respectively. At 2 and 3 months, the
ligated redness scores were significantly higher than the
spontaneous redness scores (P < 0.05). The bleeding-on-
probing data shown in Fig. 2 are expressed as the percentage
of sites which bleed after being probed. The ligated sites
increased from 50% at day zero to more than 70% by 2
months at P < 0.05. The spontaneous sites remained rela-
tively stable throughout the 6-month study, with approxi-
mately 60% of the sites exhibiting bleeding. The cavitron
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FIG. 1. Mean percentage of sites with redness scores which
increased 1 or more units over baseline values for the eight mon-
keys. The mean values for the ligated and nonligated (spontaneous)
sites are shown with standard error bars. Both ligated and sponta-
neous sites demonstrated an increase in redness scores over time at
P = 0.003 and P = 0.0016, respectively. Asterisks indicate signifi-
cant (P c 0.05) differences in spontaneous versus ligated sites.
significant reduction in the bleeding or redness baseline
scores on the nonligated side of the mouth.
The effects of ligation on attachment loss and bone loss are
shown in Fig. 3 and 4, respectively. A significant loss of
attachment of 0.38 mm per site for the ligated teeth was seen
at 1 month; this increased to 0.71 mm per site at 2 months
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FIG. 2. Mean percentage of sites which exhibited bleeding upon
probing with a constant-force probe (Florida probe, 25 g). Results
for all monkeys are pooled. The ligated sites showed a significant
increase in bleeding scores over time at P < 0.05, whereas the
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FIG. 3. Mean attachment loss in millimeters per site from the
baseline level. Results for all animals are pooled. There was a
significant increase in attachment loss over time on both sides, with
greater loss occurring with the ligated teeth (P = 0.0001), as
indicated by asterisks.
demonstrated a significant attachment loss by 2 months,
reaching 0.46 mm per site by 6 months (P = 0.001). The
ligated teeth lost significanzly more attachment than the
nonligated teeth at P = 0.0001. Both ligated and nonligated
attachment loss appeared to increase from 0 to 2 months and
plateau at 2 to 3 months. As seen in Fig. 4, there was a
significant amount of bone loss on the ligated sites when
either the 3-month or 6-month evaluation was compared to
the baseline level at P = 0.045 and P = 0.016, respectively.
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FIG. 4. Mean bone loss in millimeters per site (1 pixel = 0.1 mm)
in ligated and nonligated mandibular molar and premolar sites. The
ligated teeth demonstrated a significant loss of bone at 3 and 6
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FIG. 5. CF-PGE2 concentrations (in nanograms per milliliter) for
ligated and spontaneous sites. The mean values for pooled sites are
shown with standard error bars. CF-PGE2 levels increased threefold
and twofold over the baseline levels, respectively, for ligated and
spontaneous sites. CF-PGE2 concentrations at all sites decreased to
near baseline levels by 6 months.
ences between the ligated and spontaneous bone losses.
Compared with the baseline level, the amount of bone loss
around the spontaneous teeth was significant at 3 months
only.
Changes in inflammatory mediators. At day zero there
were no significant differences in the levels of PGE2, TxB2,
LTB4, or IL-lp in CF, comparing ligated with spontaneous
disease. Figure 5 illustrates the changes in the PGE2 con-
centrations in CF, showing all ligated sites pooled as the
open circles and all spontaneous sites as the closed circles.
By 2 months, there was a statistically significant threefold
elevation in CF-PGE2 in the ligated sites and a twofold
elevation in the spontaneous sites, as compared with base-
line levels (P = 0.041 and P = 0.008, respectively). There
were no differences in the relative elevation in the ligated
and spontaneous CF-PGE2 levels at 2 and 3 months, and
both declined towards the baseline level by 6 months. The
time-dependent changes in CF-TxB2 at ligated sites, as seen
in Fig. 6, closely paralleled the CF changes in the PGE2
levels, although the CF-TxB2 appears to peak at 2 to 3
months, suggesting it lags behind the peak in CF-PGE2
which occurs at approximately 1 to 2 months. The concen-
tration of CF-TxB2 significantly increased threefold in the
ligated sites during the first 3 months of the study, corre-
sponding to an increase from 33.7 ng/ml to 107.6 ng/ml, and
decreased to the baseline level by 6 months. The mean
CF-TxB2 concentration on the spontaneous side appears to
decrease below the baseline level; however the decrease was
not statistically significant and was probably due to the large
variability of CF-TxB2 at day zero. The ligated sites had
CF-TxB2 levels significantly higher than those of spontane-
ous sites at 3 and 6 months atP < 0.04. Thus, ligation caused
a tandem 3-month threefold rise in both cyclooxygenase
(CO) products PGE2 and TxB2, whereas only PGE2 was
shown to increase in the nonligated sites. Significant attach-
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FIG. 6. CF-TxB2 concentrations (in nanograms per milliliter) for
ligated and spontaneous sites. Asterisks indicate significant (P <
0.05) differences in spontaneous versus ligated sites. The mean
CF-TxB2 values for ligated sites increased threefold during the first
3 months and returned to the baseline level by 6 months. The
CF-TxB2 concentrations for spontaneous sites did not change sig-
nificantly from the baseline levels.
spontaneous sites, but PGE2 was the only CO product to
increase bilaterally. Thus, elevated CF-TxB2 does not ap-
pear to be an absolute requisite for disease progression in
this model.
The changes in the lipoxygenase (LO) product LTB4 are
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FIG. 7. CF-LTB4 concentrations (in nanograms per milliliter) for
ligated and spontaneous sites. Ligated sites experienced a rapid
3.6-fold increase at 1 month, followed by a decrease toward baseline
at 2 and 3 months and another rise at 6 months. Increased CF-LTB4
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FIG. 8. CF-IL-11 concentrations (in nanograms per milliliter) for
ligated and spontaneous sites. CF-IL-1,B levels rose dramatically
from near zero levels at day zero to peaks at 241.3 + 41.8 ng/ml and
181.9 + 31.7 ng/ml at 2 months for ligated and spontaneous sites,
respectively. The significant rise for both groups was short-lived and
returned to baseline levels at 6 months.
peak in LTB4 levels compared with the baseline level.
Repeated-measures ANOVA indicates that there is a time-
dependent significant rise in LTB4 levels in both ligated and
spontaneous sites over the baseline level; levels for the two
sides are not statistically different from each other. How-
ever, temporal changes of ligated LTB4 levels with a
1-month peak, followed by a trough towards the baseline
level, and a later 6-month rise are statistically significant
fluctuations. In both the ligated and nonligated sites the
increase in LTB4 levels occurred early, resulting in a signif-
icant increase in the level in CF by 1 month. Thus, the rise
in LO products, as measured by CF-LTB4, preceded the
observed increase in the CO products PGE2 and TxB2,
which increased at 2 to 3 months (compare Fig. 7 to Fig. 5
and 6).
The changes in CF-IL-1l are shown in Fig. 8. At baseline
the CF-IL-13 levels were low at both ligated and nonligated
sites (3.9 and 12.5 ng/ml, respectively). At 2 months there
was a dramatic rise in IL-lp levels, which reached peaks at
241.3 + 41.8 ng/ml and 181.9 + 31.7 ng/ml at ligated and
spontaneous sites, respectively. This rise in IL-1l is signif-
icant at P < 0.01, as compared with the baseline levels. The
short-term rise in IL-1, levels is noteworthy, as the levels
remained low at 1 month in both ligated sites and spontane-
ous sites and levels for both sites returned to the baseline
level by 6 months. Thus, the rise in IL-13 is rapid and
short-lived in this model.
As stated previously, the levels of TNF-a in the CF were
below detection limits (i.e., < 2.0 ng/ml) at all time points by
two different ELISA systems.
DISCUSSION
In this study, ligated sites lost about twice as much
attachment and bone as nonligated sites, in close agreement
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paring inflammatory mediator levels in ligated versus nonli-
gated sites demonstrates certain similarities and a few dif-
ferences in the magnitude of the mediator responses. For
example, IL-1B responses in ligated and nonligated sites are
almost identical with regard to magnitude and timing (Fig. 8).
LTB4 responses are also similar, both showing an early rise
at 1 month with a slightly elevated level at ligated sites, albeit
insignificant statistically. Similarly, both CO products PGE2
and TxB2 have higher values at 2 to 3 months in the ligated
sites than in the spontaneous sites. Thus, higher levels of
these mediators may, in part, provide an explanation for the
greater inflammation, attachment, and bone loss associated
with ligature placement.
The only mediator which did not increase in either ligated
or nonligated sites was TxB2 in spontaneous-disease pro-
gression (Fig. 6). Ligation resulted in a marked increase in
TxB2 and PGE2. PGE2 also increased in nonligated sites
without a concomitant rise in TxB2, suggesting that these CO
products are independently regulated. TxB2 is predomi-
nantly produced by both platelets and monocytes (17). PGE2
is synthesized predominantly by stimulated monocytes and
fibroblasts. The concomitant elevation of TxB2 and PGE2,
such as that observed in ligated sites, may reflect a concerted
response by platelets, monocytes, and fibroblasts. However,
the selective elevation of PGE2 without a rise in TxB2, as
seen in spontaneous-disease progression, suggests that res-
ident fibroblasts may be a major source of PGE2 in this
model. The bilateral elevation of PGE2 remains a consistent
factor for disease progression in both models. It also sug-
gests that the enhanced CO activity due to ligature place-
ment may be a result of increased monocyte and/or platelet
activation. This concept is further supported when one
examines the temporal development of the lesion.
In our previous experience with the experimental-perio-
dontitis monkey model (15), we observed a three- to fivefold
parallel increase in PGE2 and TxB2 as the dominant metab-
olite changes of the CO pathway. This rise in CF-PGE2 and
CF-TxB2 reached a peak at 3 months, which was the earliest
CF sampling period after initial ligature placement. The
present data confirm these observations with regard to both
the magnitude of the increase in PGE2 and TxB2 levels and
the temporal relationship, placing the peak CO activity at 2
to 3 months. This finding is supplemented with new evidence
for the early activation of the LO pathway preceding the
burst of CO activity. This is manifested as a threefold
increase in LTB4 which peaks or plateaus by 1 month. We
and others (2, 10) have evidence which indicates that LTB4
is produced by activated neutrophils during terminal degran-
ulation and cytolysis, presumably as a result of end-stage
confrontation with bacteria. Other cells resident in the
periodontium, such as keratinocytes, monocytes, fibro-
blasts, endothelial cells, myoblasts, platelets, mast cells,
eosinophils, and bone cells, either do not possess LO or
synthesize LO metabolites other than LTB4 (2). For exam-
ple, platelets possess LO, but they secrete 12-hydroxyeico-
satetraenoic acid (12-HETE) and not LTB4 (2). Among these
cell types, only neutrophils appear to produce significant
amounts of LTB4, and these cells are also devoid of CO
activity. These biochemical data suggest an early activation
of neutrophils in this model, an observation that closely
parallels the cellular histology of the ligature-induced peri-
odontitis lesion which has been characterized as having an
early accumulation of neutrophils (3, 4, 11, 12, 20, 21).
In the monkey model, the LTB4 increase appears to peak
or reach a plateau at 1 month, which is coincident with the
attainment of at least half the maximum inflammatory re-
sponse, as reflected in the changes in redness and bleeding
scores in this and in our previous monkey studies (14, 15).
This suggests that neutrophil activation and LTB4 play a
dominant role in initiating the superficial inflammatory re-
sponse in this early phase of this progressive lesion. In other
experiments, we examined the time course of CF-LTB4
synthesis in experimental gingivitis in humans (6). In that
study, we found a rapid rise in LTB4 by 1 week which also
preceded the rise in CO metabolites PGE2 and TxB2 which
occurred between 3 to 4 weeks. This suggests that LTB4 and
neutrophil-mediated responses play an important role in the
early development of gingival inflammation and precede
changes in CO metabolites, IL-1, or attachment loss and
bone loss. The peak attachment loss and bone loss are more
coincident with the later increase in PGE2, TxB2, and
possibly IL-1,B. This is consistent with our previous data
which failed to convincingly link gingival inflammatory
changes with CF-PGE2 and TxB2 but consistently associated
high CF-PGE2 and TxB2 levels with attachment loss and
bone loss in beagles (18), monkey (15), and humans (16).
In the monkey, the LTB4 increase is followed by a period
of increasing CO metabolites and IL-113. We envision that
this reflects a deeper penetration of bacterial challenge that
has progressed beyond the neutrophil defenses and has
stimulated the subjacent chronic macrophage infiltrate or the
newly recruited, LTB4-elicited monocytes. We would sug-
gest that this monocytic activation represents the second
phase of the lesion that would explain the later rise in levels
of PGE2 and TxB2, which are the principal CO metabolites
of these cell types. Deeper penetration of bacterial chal-
lenge, either antigenic or in the form of lipopolysaccharide
(LPS; endotoxin) would also be expected to result in mono-
cytic IL-10 release. This would explain the 2-month surge in
IL-1B secretion (Fig. 8). The potential role of IL-113 in
periodontal pathogenesis has been recently reviewed by
Page et al. (19), and new data by Stashenko et al. (25) have
demonstrated IL-1,B to be present in active human lesions.
IL-lp is principally a monocyte product that can be cose-
creted, along with PGE2 and TxB2, as a result of exposure to
either LPS or gamma interferon. Gamma interferon is a
product of antigen-stimulated T helper cells (19). Thus,
IL-1l increases may be a reflection of LPS or antigenic
penetration. Although IL-lp has many proinflammatory
properties (19), certain cellular activities are easily impli-
cated when considering the pathogenesis of periodontitis.
These include stimulation of collagenase secretion, bone
resorption, and epithelial proliferation. Thus, IL-11 may
play a key role in mediating the clinical signs of attachment
loss, pocket formation, and radiographic bone loss. PGE2 is
known to synergistically augment the inflammatory and
bone-destructive capacity of IL-1 (23). Thus, the selective
elevation of PGE2 in ligated versus nonligated sites in the
presence of equal amounts of IL-1lB may explain the in-
creased bone and attachment loss that is induced by ligation.
The observation that TNF-ax levels are below 2 ng/ml by
our detection methods is in agreement with the recent data
by Stashenko et al. (24) demonstrating the low levels of
TNF-a within inflamed periodontal tissues relative to other
cytokines such as IL-16. We have previously observed that
levels of LTB4 (17) and PGE2 (16) in tissue are 8- to 10-fold
greater than those in the adjacent CF. Thus, the tissue
TNF-ao levels reported by Stashenko et al. (0.4 ng/ml) would
be expected to be diluted below our detection threshold
within the CF. These data further suggest that PGE2 and
IL-113, rather than TNF-ot, represent principal bone-resorb-
ing molecules in this model.
INFECT. IMMUN.
GINGIVAL FLUID PGE2, TxB2, LTB4, AND IL-lp 1459
In summary, these new biochemical data suggest a two-
stage lesion. The first stage involves bacterial or neutrophil
confrontation accompanied by LTB4 release and clinical
gingival inflammation. Thus, LTB4 probably serves to re-
cruit and activate neutrophils and monocytes. Near the end
of this stage, there is also some mild activation of the CO
pathway with slight elevations in PGE2 and TxB2. During the
second stage of the lesion, the neutrophil defenses are
overcome with full activation of the underlying monocytic
cell lineage probably due to deeper LPS and antigenic
penetration. This monocytic activation is accompanied by
high levels of PGE2, TxB2, and IL-11 secretion with ensuing
loss of attachment and bone.
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